In last trading session, the stock price of Plandai Biotechnology Inc (OTCMKTS:PLPL) started weak and then recoup its losses to close the week at $0.140. IN today’s session, the stock is trading flat around last session closing levels. Recently, the company reported that the revenue in the quarter completed March 31, 2015 came at $21,744 versus $12,554 reported in the same period in 2014.
This included the revenue generated from timber sale from the tea estate segment in South Africa. Also, the company reported a jump on cost of sales resulting from additional factory expenses and other costs.
Can Cannabis Science Inc (OTCMKTS:CBIS) Extend Its Gain?
Since the start of this year, Cannabis Science Inc (OTCMKTS:CBIS) stock has been moving down on the charts on thin volumes. It was expected as the stock was overpriced and there was nothing specific to support such a massive market cap. The major problem with the company is that it is still very negligent in filing the essential reports. Back in August, the company submitted an NT 10-K. However, the annual report is still not submitted to this day and the figures contained in last period looked quite dismal.
Last week, the company reported that it filed initial Schedule 14C filing so as to complete dividend payout process of the application filed on August 18, 2011. This new application intends to cover all of company’s shareholders in the growth curve.
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) Obtains Grant
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) reported that the company received a Fast Track SBIR grant from the NCI, NIH. This grant will help company to advance its preclinical trials examining the safety of intravenous injection of “Tc99m tilmanocept.” The company has obtained the first part of grant amounting to $300,000 that will be used for completing deals and getting IRB approvals.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: